Cellectar Q2 net loss $6.9M; cash $34M; Phase 3 iopofosine trial site activation started

Cellectar Biosciences, Inc.

2026-Q2 EPS reported -$1.52

Net loss $6.9M ($0.57/share) vs $5.4M ($3.39/share) in Q2 2025; R&D up to $4.6M from $2.4M.
Cash $34.0M at June 30, 2026 vs $13.2M at Dec 31, 2025; funded into Q2 2027.
Initiated site activation for confirmatory Phase 3 iopofosine I 131 in WM; NDA planned mid-2027 under accelerated approval.
Dosed first patients in Phase 1b CLR 125 for triple-negative breast cancer.
May 2026 financing: ~$35M upfront, up to $105M milestone-based securities to fund Phase 3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.